Venous Thromboembolism: Risk Factors and Prophylaxis

Rita Selby; William H. Geerts

doi:10.1055/s-2000-13189

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2000; 21(6): 477-486
DOI: 10.1055/s-2000-13189

Venous Thromboembolism: Risk Factors and Prophylaxis

Rita Selby¹ , William H. Geerts²

In recent years, Dr. Geerts has received research funding from Aventis Pharma and Pharmacia, manufacturers of anticoagulant drugs. However, in the article, no specific drug is named or recommended.
¹Division of Hematology, Departments of Medicine and Health Administration, Clinical Epidemiology and Health Services Research Unit, Sunnybrook and Women's College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
²Division of Respiratory Diseases and the Thromboembolism Program, Departments of Medicine and Health Administration, Clinical Epidemiology and Health Services Research Unit, Sunnybrook and Women's College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada

Abstract

ABSTRACT

Venous thromboembolism is a common disease in the community and the most frequent preventable cause of hospital death. Acquired and inherited risk factors for thrombosis have been extensively studied over the past two decades. These factors and the clinical setting allow the stratification of most hospitalized patients into low-, moderate-, and high-risk groups. For patients in the moderate- and high-risk categories, routine thromboprophylaxis can decrease the morbidity and mortality from thromboembolic complications as well as reduce patient care expenditures. Low-dose heparin is generally the most appropriate prophylaxis for moderate-risk patients, and either low molecular weight heparin or adjusted-dose warfarin is generally the most appropriate for high-risk patients.

KEYWORD

Thromboembolism - risk factors - prophylaxis

Full Text

References

REFERENCES

1 Anderson F A, Wheeler H B, Goldberg R J. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT study. Arch Intern Med . 1991; 151 933-938
2 Nordstrom M, Lindblad B, Bergqvist D. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med . 1992; 232 155-160
3 Hansson P-O, Welin L, Tibblin G. Deep vein thrombosis and pulmonary embolism in the general population: ``The study of men born in 1913''. Arch Intern Med . 1997; 157 1665-1670
4 Silverstein M D, Heit J A, Mohr D N. Trends in the incidence of deep vein thrombosis and pulmonary embolism. A 25-year population-based study. Arch Intern Med . 1998; 158 585-593
5 Virchow R. Cellular Pathology as Based upon Physiological and Pathologic Histology: Local Formation of Fibrin. London: Churchill 1860
6 Clagett G P, Anderson F A, Geerts W. Prevention of venous thromboembolism. Chest . 1998; 114(Suppl) 531S-560S
7 Geerts W H, Heit J A, Clagett G P. Prevention of venous thromboembolism. Chest. 2000; 118 (in press)
8 Lowe G DO, Haverkate F, Thompson S G. Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: The ECAT DVT Study. Thromb Haemost . 1999; 81 879-886
9 Geerts W H, Code K I, Jay R M. A prospective study of venous thromboembolism after major trauma. N Engl J Med . 1994; 331 1601-1606
10 Abelseth G, Buckley R E, Pineo G E. Incidence of deep-vein thrombosis in patients with fractures of the lower extremity distal to the hip. J Orthop Trauma . 1996; 10 230-235
11 Prandoni P, Lensing A WA, Buller H R. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med . 1992; 327 1128-1133
12 Nordstrom M, Lindblad B, Anderson H. Deep venous thrombosis and occult malignancy: an epidemiological study. BMJ . 1994; 308 891-894
13 Sorensen H T, Mellemkjaer L, Steffensen F H. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med . 1998; 338 1169-1173
14 Falanga A, Rickles F R. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost . 1999; 25 173-182
15 Saphner T, Tormey D C, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol . 1991; 9 286-294
16 Piccioli A, Prandoni P, Ewenstein B M. Cancer and venous thromboembolism. Am Heart J . 1996; 132 850-855
17 Monreal M, Prandoni P. Venous thromboembolism as first manifestation of cancer. Semin Thromb Hemost . 1999; 25 131-136
18 Baron J A, Gridley G, Weiderpass E. Venous thromboembolism and cancer. Lancet . 1998; 351 1077-1080
19 Prandoni P, Lensing A WA, Cogo A. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med . 1996; 125 1-7
20 Heit J A, Mohr D N, Silverstein M D. Predictors of recurrence after deep vein thrombosis and pulmonary embolism. A population-based cohort study. Arch Intern Med . 2000; 160 761-768
21 Treffers P E, Huidekoper B L, Weenink G H. Epidemiological observations of thrombo-embolic disease during pregnancy and in the puerperium, in 56,022 women. Int J Gynaecol Obstet . 1983; 21 327-331
22 McColl M D, Ramsay J E, Tait R C. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost . 1997; 78 1183-1188
23 Bonnar J. Can more be done in obstetric and gynecologic practice to reduce morbidity and mortality associated with venous thromboembolism?. Am J Obstet Gynecol . 1999; 180 784-791
24 Brill-Edwards P, Ginsberg J, on behalf of the ROCIT investigators. Safety of withholding antepartum heparin despite previous thromboembolism (VTE). Thromb Haemost . 1999; 82 664 (abstr)
25 Douketis J D, Ginsberg J S, Holbrook A. A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy. Arch Intern Med . 1997; 157 1522-1530
26 Bloemenkamp K WM, Rosendaal F R, Buller H R. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med . 1999; 159 65-70
27 Vandenbroucke J P, Koster T, Briet E. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet . 1994; 344 1453-1457
28 Grady D, Wenger N K, Herrington D. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med . 2000; 132 689-696
29 Rosendaal F R. Risk factors for venous thrombotic disease. Thromb Haemost . 1999; 82 610-619
30 Baglin T P, White K, Charles A. Fatal pulmonary embolism in hospitalised medical patients. J Clin Pathol . 1997; 50 609-610
31 Baum G L, Fisher F D. The relationship of fatal pulmonary insufficiency with cor pulmonale, right sided mural thrombi and pulmonary emboli: a preliminary report. Am J Med Sci . 1960; 240 609-612
32 Ryan S F. Pulmonary embolism and thrombosis in chronic obstructive emphysema. Am J Pathol . 1963; 43 767-773
33 Mitchell R S, Silvers G W, Dart G A. Clinical and morphologic correlations in chronic airway obstruction. Am Rev Respir Dis . 1968; 97 54-62
34 Moser K M, LeMoine J R, Nachtwey F J. Deep venous thrombosis and pulmonary embolism. Frequency in a respiratory intensive care unit. JAMA . 1981; 246 1422-1424
35 Carson J L, Terrin M L, Duff A. Pulmonary embolism and mortality in patients with COPD. Chest . 1996; 110 1212-1219
36 Fraisse F, Holzapfel L, Coulaud J-M. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. Am J Respir Crit Care Med . 2000; 161 1109-1114
37 Schonhofer B, Kohler D. Prevalence of deep-vein thrombosis of the leg in patients with acute exacerbation of chronic obstructive pulmonary disease. Respiration . 1998; 65 173-177
38 Ferrari E, Chevallier T, Chapelier A. Travel as a risk factor for venous thromboembolic disease. A case-control study. Chest . 1999; 115 440-444
39 Hansson P-O, Eriksson H, Welin L. Smoking and abdominal obesity. Risk factors for venous thromboembolism among middle-aged men: ``The Study of men born in 1913''. Arch Intern Med . 1999; 159 1886-1890
40 Bick R L, Kaplan H. Syndromes of thrombosis and hypercoagulability: congenital and acquired thrombophilias. Clin Appl Thromb Hemost . 1998; 4 25-50
41 Bertina R M. Molecular risk factors for thrombosis. Thromb Haemost . 1999; 82 601-609
42 Rees D C, Cox M, Clegg J B. World distribution of factor V Leiden. Lancet . 1995; 346 1133-1134
43 Koster T, Rosendaal F R, de Ronde H. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet . 1993; 342 1503-1506
44 Ridker P M, Hennekens C H, Lindpaintner K. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med . 1995; 332 912-917
45 Rosendaal F R, Doggen C JM, Zivelin A. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost . 1998; 79 706-708
46 Poort S R, Rosendaal F R, Reitsma P H. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood . 1996; 88 3698-3703
47 Bick R L, Baker W F. Antiphospholipid syndrome and thrombosis. Semin Thromb Hemost . 1999; 25 333-350
48 Triplett D A. Many faces of lupus anticoagulants. Lupus . 1998; 7(Suppl 2) S18-S22
49 Eichinger S, Stumpflen A, Hirschl M. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost . 1998; 80 566-569
50 den Heijer M, Koster T, Blom H J. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med . 1996; 334 759-762
51 Ray J G. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med . 1998; 158 2101-2106
52 Langman L J, Ray J G, Evrovski J. Hyperhomocyst(e)inemia and the increased risk of venous thromboembolism: More evidence from a case-control study. Arch Intern Med . 2000; 160 961-964
53 Ridker P M, Hennekens C H, Selhub J. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation . 1997; 95 1777-1782
54 Gemmati D, Previati M, Serino M L. Low folate levels and thermolabile methylenetetrahydrofolate reductase as primary determinant of mild hyperhomocystinemia in normal and thromboembolic subjects. Arterioscler Thromb Vasc Biol . 1999; 19 1761-1767
55 Second Thromboembolic Risk Factors (THRiFT II) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. Phlebology . 1998; 13 87-97
56 Paiement G D, Wessinger S J, Harris W H. Cost-effectiveness of prophylaxis in total hip replacement. Am J Surg . 1991; 161 519-524
57 Bergqvist D. Cost-effectiveness of venous thromboembolism prophylaxis in surgery. Eur J Surg . 1994; S571 49-53
58 Mamdani M M, Weingarten C M, Stevenson J G. Thromboembolic prophylaxis in moderate-risk patients undergoing elective abdominal surgery: decision and cost-effectiveness analyses. Pharmacotherapy . 1996; 16 1111-1127
59 Hull R D, Raskob G E, Pineo G F. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. Arch Intern Med . 1997; 157 298-303
60 Brennand J E, Greer I A. Thromboembolism in gynaecological surgery. Curr Obstet Gynaecol . 1998; 8 44-48
61 SOGC/GOC/SCC Policy and Practice Guideline Committee. Prevention and treatment of thrombo-embolic disease in gynaecological surgery. J Soc Obstet Gynaecol Can . 1999; 21 1087-1094
62 Kibel A S, Loughlin K R. Pathogenesis and prophylaxis of postoperative thromboembolic disease in urological pelvic surgery. J Urol . 1995; 153 1763-1774
63 Nurmohamed M T, van Riel M A, Henkens C MA. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost . 1996; 75 233-238
64 Agnelli G, Piovella F, Buoncristiani P. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med . 1998; 339 80-85
65 Agnelli G. Prevention of venous thromboembolism after neurosurgery. Thromb Haemost . 1999; 82 925-930
66 Pineo G F, Hull R D. Prophylaxis of venous thromboembolism following orthopedic surgery: mechanical and pharmacological approaches and the need for extended prophylaxis. Thromb Haemost . 1999; 82 918-924
67 Francis C W, Pellegrini V D, Totterman S. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. J Bone Joint Surg . 1997; 79A 1365-1372
68 Hull R D, Pineo G F, Francis C W. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery versus warfarin in hip arthroplasty patients: a double-blind, randomized comparison. Arch Intern Med . 2000; 160 2199-2207
69 White R H, Romano P S, Zhou H. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med . 1998; 158 1525-1531
70 Geerts W H, Jay R M, Code K I. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med . 1996; 335 701-707
71 Samama M M, Cohen A T, Darmon J-Y. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med . 1999; 341 793-800
72 Mismetti P, Laporte-Simitsidis S, Tardy B. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost . 2000; 83 14-19
73 Durieux P, Nizard R, Ravard P. A clinical decision support system for prevention of venous thromboembolism. Effect on physician behavior. JAMA . 2000; 283 2816-2821